Hypogen

Business Services · Virginia, United States · 1-10 Employees

View Company Info for Free

Overview

Headquarters

1841 Fendall Ave, Charlottesville, Virgi...

Phone Number

(434) 466-1131

Revenue

<$5 Million

Industry

Business Services Research & Development
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1

About Hypogen

Hypogen, Inc., is a biopharmaceutical company focused on the development of novel diagnostic tests and new therapeutics for essential hypertension. Hypertension is the worlds most prevalent disease, affecting more than 25 percent of the population, and continues to be a leading cause of morbidity and mortality. The National Heart, Lung, and Blood Institute reports that more than 30 percent of Americans with hypertension are unaware that they have high blood pressure, and less than 25 percent of those with hypertension actually have their condition controlled by prescription medications. As a result, it is estimated that more that 50 million people in the United States alone stand to benefit from improved diagnostic methods and more effective therapies. Hypogens mission is to meet this need. Hypogen has discovered and characterized a proprietary set of gene polymorphisms that it believes are largely responsible for the pathogenesis of essential hypertension and salt sensitivity. These sRead more
Popular SearchesHypogen IncHypogenHypogen LLCHippogen IncSIC Code 87,873NAICS Code 54,541Show more

Is Hypogen your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Compare Similar Companies to Hypogen

Compare insights from companies similar to Hypogen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.

Company Name

Revenue

Number of Employees

Type

Funding

Founded In

Top Executive

Hypogen

<$5M
1-10
Private
-
2002
N/A
$10.5M
1-10
Private
-
2010
GX
Gaoping XiaoVice President, Business Development
$5.4M
11-50
Private
-
2013
GC
Guoqing ChenPresident & CEO
<$5M
11-50
Private
-
1996
KD
Krisha DoshiManager, Product Marketing
<$5M
11-50
Private
<$5M
1997
MW
Marisa WestlinDirector, Business Development
<$5M
11-50
Private
-
2014
JU
Jorge UrrestiAssociate Director and Stem Cell Disease Models
<$5M
11-50
Private
-
2004
Illustration of an envelope

Company Profile Activity

i

Among all Business Services companies

Low Activity

High Activity

Activity Insights

Hypogen is experiencing very low activity levels compared to other companies in the Business Services sector.

What does this means?

Hypogen is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Hypogen.

Top Business Services Companies

Frequently Asked Questions Regarding Hypogen

What is Hypogen's official website?
Hypogen's official website is www.hypogen.com
What is Hypogen's Revenue?
Hypogen's revenue is <$5 Million
What is Hypogen's SIC code?
Hypogen's SIC: 87,873
What is Hypogen's NAICS code?
Hypogen's NAICS: 54,541
How many employees does Hypogen have?
Hypogen has 1-10 employees
What industry does Hypogen belong to?
Hypogen is in the industry of: Business Services, Research & Development
What is Hypogen competition?
Hypogen top competitors include: iXCells Biotechnologies, G&P Biosciences, ExonBIO, Multispan
How do I contact Hypogen?
Hypogen contact info: Phone number: (434) 466-1131 Website: www.hypogen.com
What does Hypogen do?

Hypogen, Inc., is a biopharmaceutical company focused on the development of novel diagnostic tests and new therapeutics for essential hypertension. Hypertension is the worlds most prevalent disease, affecting more than 25 percent of the population, and continues to be a leading cause of morbidity and mortality. The National Heart, Lung, and Blood I... nstitute reports that more than 30 percent of Americans with hypertension are unaware that they have high blood pressure, and less than 25 percent of those with hypertension actually have their condition controlled by prescription medications. As a result, it is estimated that more that 50 million people in the United States alone stand to benefit from improved diagnostic methods and more effective therapies. Hypogens mission is to meet this need. Hypogen has discovered and characterized a proprietary set of gene polymorphisms that it believes are largely responsible for the pathogenesis of essential hypertension and salt sensitivity. These single-nucleotide polymorphisms (SNPs), by themselves or via an interaction with genes controlling the renin-angiotensin system, have a strong positive association with essential hypertension across racial and ethnic subpopulations, including Ghanaians, Caucasian Americans, Japanese, and Italians. Furthermore, Hypogen has successfully isolated and immortalized human cells expressing the GRK4 gene variants, as well as expressed the genes both in vitro (i.e., in transfected cells) and in vivo (creating the first transgenic hypertensive mouse model expressing specific genes that cause these mice to become either hypertensive or salt sensitive). These novel drug discovery tools promise to eliminate two of the primary bottlenecks in the search for new antihypertensive drugs. Armed with the knowledge of the specific mechanisms responsible for the disease, Hypogens first objective is to provide the clinical and research communities with a more accurate method for diagnosing essential hypertension. As currently practiced, diagnosis is ...Read More

Is Hypogen a public company?
Hypogen is private company therefore does not currently have an official ticker symbol
See more information about Hypogen

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.